Abstract:Objective To understand the mechanism of the resistance of non‐small cell lung cancer (NSCLC) to epidermal growth factor receptor (EGFR) inhibitor treatment. Background NSCLC is one of the most common malignancies in the world, of which a group of patients have activating EGFR mutations. Icotinib and Gefitinib are two tyrosine kinase inhibitors (TKIs) that bind to the tyrosine kinase domain in EGFR and inhibit EGFR activity, which have been used to treat NSCLC. However, natural and acquired resistance significantly limits the efficacy of EGFR‐TKIs, and the mechanism of the resistance is not fully understood. Autophagy is a highly conserved, genetically programmed degradation pathway that removes damaged organelles and protein aggregates in response to various stimuli to maintain cellular homeostasis. Autophagy inhibits tumorigenesis but promotes tumor progression at later stages. Nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) is a transcription factor and regulates the expression of antioxidant genes. Activation of Nrf2 is a protective mechanism for normal cells under oxidative stress, and also for cancer cells from chemotherapeutic agents that facilitates cancer progression. Whether autophagy and Nrf2 activation contribute to the sensitivity of NSCLC to TKI treatment has been incompletely understood. Methods We compared the sensitivity of A549, an EGFR wild type cell line derived from lung carcinoma, and HCC827, an EGFR mutant cell line derived from lung adenocarcinoma, to TKI treatment, and determined the role of autophagy and Nrf2 activation in TKI‐mediated cell death. Results Icotinib and Gefitinib induced significant apoptosis in HCC827 cells in a dose‐dependent manner, while they did not cause apoptosis in A549 cells. TKI inhibitors induced autophagy flux and mTOR inhibition in HCC827 but not in A549 cells. Intriguingly, suppression of autophagy by chloroquine, a lysosomal inhibitor, did not affect TKI‐induced cell death. A549 cells had lower basal level of autophagy but higher basal level of Nrf2 activation than HCC827 cells. Brusatol, a Nrf2 inhibitor, did not affect autophagy in A549 or HCC827 cells, but significantly decreased the cell viability in A549 and HCC827 cells. However, Brusatol did not further sensitize A549 or HCC827 cells to TKI‐induced cell death. Conclusion A549 cells are more resistant to TKI‐induced apoptosis than HCC827 due to persistent activation of Nrf2. Although autophagy activity is higher in HCC827 cells than A549 cells, it is not essential for the sensitivity of HCC827 or A549 cells for TKI. Inhibition of Nrf2 reduces the cell viability of TKI resistant A549 cells although it does not show synergistic effects with TKI. Support or Funding Information NIH RO1 AA020518, NIH R01 DK 102142, P20 RR021940 (COBRE)

Inhibition of Autophagy by YC-1 Promotes Gefitinib Induced Apoptosis by Targeting FOXO1 in Gefitinib-Resistant NSCLC Cells

YC-1 Potentiates the Antitumor Activity of Gefitinib by Inhibiting HIF-1α and Promoting the Endocytic Trafficking and Degradation of EGFR in Gefitinib-Resistant Non-Small-cell Lung Cancer Cells

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

Foxm1 Mediated Resistance to Gefitinib in Non-Small-Cell Lung Cancer Cells

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC Via Promoting Autophagy.

Overcoming Gefitinib Resistance in Nsclc Via Inactivation of the Pi3k/Akt Signaling Pathway by A Combination of Fus1 Nanoparticles and Egfr Inhibitors.

EGFR Tyrosine Kinase Inhibitors Activate Autophagy As a Cytoprotective Response in Human Lung Cancer Cells

Gefitinib selectively targets non-small cell lung cancer cells through inhibition of Forkhead box M1

Role of Insulin-Like Growth Factor 1 in Drug Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer

GLRX Inhibition Enhances the Effects of Geftinib in EGFR-TKI-resistant NSCLC Cells Through FoxM1 Signaling Pathway

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells.

Nrf2 but Not Autophagy Activation is Associated with Resistance to Egfr Inhibitor-Induced Lung Tumor Cell Apoptosis

An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer.

FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer.

Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer